# Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis

> **NCT06578637** · NA · RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 20 (estimated)

## Conditions studied

- FAP
- Familial Adenomatous Polyposis

## Interventions

- **DIETARY_SUPPLEMENT:** R-1,3-Butanediol (10G-A)
- **DIETARY_SUPPLEMENT:** R-1,3-Butanediol (20G-A)
- **DIETARY_SUPPLEMENT:** R-1,3-Butanediol (30G-A)
- **DIETARY_SUPPLEMENT:** R-1,3-Butanediol (30G-B)

## Key facts

- **NCT ID:** NCT06578637
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-20
- **Primary completion:** 2027-10
- **Final completion:** 2027-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06578637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06578637, "Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06578637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*